Drug intelligence / Profile preview

TEE-Fumarase

Development stage: Preclinical
Lead developer: Apteeus
Modality: Small Molecules

Overview

TEE-Fumarase is a preclinical drug candidate being developed by **Apteeus** for the treatment of **fumarase deficiency** (also known as fumaric aciduria). Fumarase deficiency is a rare, severe autosomal recessive metabolic disorder caused by a deficiency of the enzyme fumarate hydratase, which is a critical component of the Krebs cycle. TEE-Fumarase was identified using Apteeus's proprietary **TEE (Therapeutic Effect Enhancement)** platform, which screens for small molecules capable of restoring or enhancing the activity of deficient enzymes. The program aims to provide a targeted therapeutic option for patients suffering from the neurological and metabolic complications associated with this condition.

Other names: TEE-Fumarase

Targets

FH (Fumarate hydratase)

Beyond the preview

Go deeper on TEE-Fumarase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEE-Fumarase.

Explore the full profile